Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Altered bioavailability of platelet-derived factor VIII during thrombocytosis reverses phenotypic efficacy in haemophilic mice.

Thrombosis and haemostasis - 1 Dec 2008

Damon Andrea L, Scudder Lesley E, Gnatenko Dmitri V, Sitaraman Varsha, Hearing Patrick, Jesty Jolyon, Bahou Wadie F

Abstract excerpt

Ectopic delivery of factor VIII (FVIII) to megakaryocytes (Mk) represents a viable approach for localized tenase generation by concentrating the FVIIIa/FIXa enzyme-cofactor complex onto activated platelet membranes. We utilized a core rat platelet factor 4 (PF4) promoter for Mk/platelet-restricted expression of human B-domain-deleted (hBDD) FVIII within the background of a haemophilia A mouse...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Coagulation Tests
Share to Cytoplasmic Granules

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Factor Xa

Share to Megakaryocytes

Share to Platelet Activation

Share to Platelet Count

Share to Thrombocytosis

Share to Thrombopoietin

Source

Identifiers

PMID: 19132238
DOI: 10.1160/th08-04-0242

Genes

TPO

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Altered bioavailability of platelet-derived factor VIII during thrombocytosis reverses phenotypic efficacy in haemophilic mice.PMID 19132238Read ↗

The severe spontaneous bleeding phenotype in a novel hemophilia A rat model is rescued by platelet FVIII expression.Semantic proximity Read ↗

Absence of hematopoietic tissue factor pathway inhibitor mitigates bleeding in mice with hemophilia.Semantic proximity Read ↗

Targeting factor VIII expression to platelets for hemophilia A gene therapy does not induce an apparent thrombotic risk in mice.Semantic proximity Read ↗

In vivo enrichment of genetically manipulated platelets corrects the murine hemophilic phenotype and induces immune tolerance even using a low multiplicity of infection.Semantic proximity Read ↗

The murine platelet and plasma factor V pools are biosynthetically distinct and sufficient for minimal hemostasis.Semantic proximity Read ↗

Platelet-delivered therapeutics.Semantic proximity Read ↗

A Thrombin-Activatable Factor X Variant Corrects Hemostasis in a Mouse Model for Hemophilia A.Semantic proximity Read ↗

Comparison of platelet-derived and plasma factor VIII efficacy using a novel native whole blood thrombin generation assay.Semantic proximity Read ↗

Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies.Semantic proximity Read ↗

Limiting prothrombin activation to meizothrombin is compatible with survival but significantly alters hemostasis in mice.Semantic proximity Read ↗

Factor IX ectopically expressed in platelets can be stored in alpha-granules and corrects the phenotype of hemophilia B mice.Semantic proximity Read ↗

Cre/lox Studies Identify Resident Macrophages as the Major Source of Circulating Coagulation Factor XIII-A.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.